| Type 2 Diabetes Mellitus |
1 |
1 |
| Genomic Medicine |
0 |
0.8 |
| Precision Medicine |
0 |
0.62 |
| Metabolic Syndrome |
0 |
0.58 |
| Biologic Therapy |
0 |
0.54 |
| Metabolism |
0 |
0.54 |
| Genetics |
0 |
0.41 |
| Genetic Testing |
0 |
0.35 |
| Insulin Resistance |
0 |
0.17 |
| Type 1 Diabetes Mellitus |
0 |
0.16 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.13 |
| Diabetes Mellitus |
0 |
0.12 |
| Diet |
0 |
0.12 |
| Epigenetics |
0 |
0.12 |
| Hyperglycemia |
0 |
0.12 |
| Continuous Glucose Monitoring |
0 |
0.11 |
| Biliary Disease |
0 |
0.1 |
| Leukemia |
0 |
0.1 |
| Targeted Cancer Therapy |
0 |
0.1 |
| Fatty Liver |
0 |
0.09 |
| Liver Disease |
0 |
0.09 |
| Adverse Effects |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Cancer |
0 |
0.08 |
| Cardiovascular Risk Management |
0 |
0.08 |
| Dementia |
0 |
0.08 |
| DPP-4 Inhibitors |
0 |
0.08 |
| Lipids Management |
0 |
0.08 |
| Liver |
0 |
0.08 |
| Cerebrovascular Accident |
0 |
0.07 |
| Toxicology |
0 |
0.07 |
| High Density Lipoprotein (HDL) cholesterol |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |
| Psoriasis |
0 |
0.06 |